1-(1-methyl-1H-imidazol-2-yl)ethanol | 41507-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(1-methyl-1H-imidazol-2-yl)ethanol
• 英文别名: 1-(1-methylimidazol-2-yl)ethanol
• CAS: 41507-36-2
• 化学式: C₆H₁₀N₂O
• 分子量: 126.158
• InChiKey: RZNHHGMCDDENDY-UHFFFAOYSA-N

物化性质

• 沸点：
  260.5±23.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  1-(1-methyl-1H-imidazol-2-yl)ethanol 在 盐酸 、 manganese(IV) oxide 、 氢氧化钾 、 氯化亚砜 、 sodium azide 作用下， 以 乙醇 、 氯仿 、 丙酮 、 苯 为溶剂， 反应 60.0h， 生成 6-Methyl-2-(1-methyl-1H-imidazol-2-yl)-quinolin-4-ylamine
  参考文献：
  名称：

  取代的2-（1-甲基-2-咪唑基）喹啉的合成

  摘要：

  甲基锂与1-甲基1-2-咪唑甲醛的反应得到相应的醇2。用二氧化锰氧化化合物2得到2-乙酰基1-1-甲基咪唑（3）。使用化合物3和取代的靛红4，制备了相应的喹啉-4-羧酸（5）。5的酸咪唑化物与适当的胺反应生成酰胺6。通过库尔修斯重排以高收率制备氨基甲酸酯10。取代的喹啉-4-胺13通过化合物的酸水解而获得的10（R 1 =吨-Bu）。胺13与二烷基氨基烷基氯的烷基化得到化合物14。

  DOI：

  10.1002/jhet.5570340526
• 作为产物：
  描述：

  1-(1-甲基-1H-咪唑-2-基)乙酮 在 甲醇 、 sodium tetrahydroborate 作用下， 生成 1-(1-methyl-1H-imidazol-2-yl)ethanol
  参考文献：
  名称：

  铝催化不对称硼氢化杂芳基酮

  摘要：

  发现一系列带有手性双酚型配体的甲基铝配合物是杂环酮不对称还原的高活性催化剂（S/C = 100 - 500，ee 高达 99%）。该协议适用于广泛的底物，并且对官能团具有很高的耐受性。形成的 2-杂环醇是药物发现中的重要组成部分，或可用作不对称催化中的配体。反应中间体的分离和综合表征支持 DFT 计算提出的催化循环。

  DOI：

  10.1021/jacs.9b10364

文献信息

• [EN] 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS<br/>[FR] DÉRIVÉS DE 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHÉNYL)-URÉE UTILISÉS COMME INHIBITEURS DE CXCR2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015181186A1

  公开（公告）日：2015-12-03

  The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

  这项发明涉及1-(3-磺酰基苯基)-3-(环戊-2-烯-1-基)脲衍生物，以及它们在治疗或预防由CXCR2受体介导的疾病和症状中的应用。此外，该发明涉及含有这些衍生物的组合物和它们的制备方法。
• METAL NANOPARTICLE-BASED CATALYTIC COMPOSITION THAT CONTAINS A NITROGEN-CONTAINING LIGAND IN AN IONIC LIQUID, PROCESS FOR PREPARATION, PROCESS FOR HYDROGENATION OF AN OLEFINIC FEEDSTOCK
  申请人：Leger Bastien-Thésards

  公开号：US20100191027A1

  公开（公告）日：2010-07-29

  The object of this invention is a suspension of metal nanoparticles with a mean size of between 1 and 20 nanometers, in at least one non-aqueous ionic liquid, whereby said suspension also contains at least one nitrogen-containing ligand, in which said metal nanoparticles comprise at least one transition metal in the zero valence state that is selected from among rhodium, ruthenium, iridium, nickel, and platinum by themselves or in a mixture and in which said nitrogen-containing ligand is selected from the group that is formed by the linear compounds that comprise at least one nitrogen atom, whereby the non-aromatic cyclic compounds comprise at least one nitrogen atom, the non-condensed aromatic compounds comprise at least one nitrogen atom, the condensed aromatic compounds comprise at least one group of two aromatic cycles that are condensed two by two, and at least one nitrogen atom, whereby the condensed aromatic compounds comprise at least 3 aromatic cycles and 1 nitrogen atom, and whereby the condensed aromatic compounds comprise at least 3 aromatic cycles and at least 2 nitrogen atoms that are located in the same aromatic cycle.

  本发明的目的是提供一种金属纳米颗粒的悬浮液，其平均尺寸在1到20纳米之间，在至少一种非水离子液体中，该悬浮液还包含至少一种含氮配体，其中所述金属纳米颗粒至少包括一种零价态的过渡金属，所述过渡金属选自铑、钌、铱、镍和铂，可以单独使用或混合使用，并且所述含氮配体选自由至少一种氮原子组成的线性化合物组成的组，其中非芳香环化合物包括至少一个氮原子，非缩合芳香化合物包括至少一个氮原子，缩合芳香化合物包括至少两个芳香环两两缩合的一个氮原子组，至少三个芳香环和一个氮原子，缩合芳香化合物包括至少三个芳香环和至少两个位于同一芳香环中的氮原子。
• ACETONITRILE REMOVAL FROM THE OLEFINIC FEED OF ETHER PRODUCTION PROCESSES USING IONIC LIQUIDS
  申请人：Cadours Renaud

  公开号：US20080154068A1

  公开（公告）日：2008-06-26

  An enhanced ether production process from an olefinic cut containing at least one iso-olefin and from an alcohol comprises a stage of removal of the acetonitrile present in the hydrocarbon feed by liquid-liquid extraction, the extraction solvent being a non-aqueous ionic liquid of general formula Q + A − , wherein Q + is an ammonium, phosphonium and/or sulfonium cation, and A − an anion likely to form a liquid salt with said cation. Advantageously, the method according to the invention generally allows the amount of water at the etherification reactor inlet to be divided by at least two and thus the purity of the ether produced to be improved.

  一种改进的醚生产工艺，从含有至少一种异构烯烃和醇的烯烃馏分中进行，包括通过液液萃取去除烃原料中存在的乙腈的阶段，萃取溶剂为一般式Q+A−的非水离子液体，其中Q+是铵、磷铵和/或磺铵阳离子，A−是可能与该阳离子形成液态盐的阴离子。优选，根据本发明的方法通常允许将醚化反应器入口处的水量至少减少一半，从而提高所生产醚的纯度。
• PROCESS FOR HYDROGENATION OF AN AROMATIC FEEDSTOCK THAT AS CATALYST USES A SUSPENSION OF METAL NANOPARTICLES CONTAINING A NITROGEN-CONTAINING LIGAND IN AN IONIC LIQUID
  申请人：Leger Bastien Thesards

  公开号：US20100228064A1

  公开（公告）日：2010-09-09

  This invention describes a process for hydrogenation of an aromatic feedstock that as a catalytic composition uses a suspension of metal nanoparticles of a mean size of between 1 and 20 nanometers in at least one non-aqueous ionic liquid, whereby said suspension also contains at least one nitrogen-containing ligand, in which said metal nanoparticles comprise a transition metal in the zero-valence state, whereby the transition metal is selected from the groups 8, 9, 10 and 11 of the periodic table and in which said nitrogen-containing ligand comprises 1 to n nitrogen atoms, whereby n is an integer of between 1 and 20.

  这项发明描述了一种对芳香原料进行氢化的过程，其催化组合物使用至少一种非水离子液体中平均尺寸在1至20纳米之间的金属纳米颗粒的悬浮液，该悬浮液还包含至少一种含氮配体，其中所述金属纳米颗粒包括零价态的过渡金属，所述过渡金属选自周期表的8、9、10和11族，并且所述含氮配体包括1到n个氮原子，其中n是介于1和20之间的整数。
• Novel aminopyrimidine derivatives as PLK1 inhibitors
  申请人：Hashihayata Takashi

  公开号：US20080305081A1

  公开（公告）日：2008-12-11

  The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R 1 and R 2 , which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R 3 and R 4 , which may be the same or different, are each a hydrogen atom, a lower alkyl group, NR a R b , a phenyl group, a lower alkyl group substituted with a phenyl group, a 4- to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5- or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5- or 6-membered aromatic heterocyclic group, or the like; and R 5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

  本发明涉及由公式[I]表示的化合物，或其药学上可接受的盐或酯，其中R1和R2（可以相同也可以不同）分别是氢原子、低碳基、环烷基或类似物；R3和R4（可以相同也可以不同）分别是氢原子、低碳基、NRaRb、苯基、带苯基的低碳基、4-至7-成员的脂环杂环基、带4-至7-成员的脂环杂环基的低碳基、5-或6-成员的芳香杂环基、带5-或6-成员的芳香杂环基的低碳基或类似物；R5是氢原子、氰基、卤素原子或低碳基。